Edition:
United States

Edge Therapeutics Inc (EDGE.OQ)

EDGE.OQ on NASDAQ Stock Exchange Global Select Market

0.94USD
22 May 2018
Change (% chg)

$0.03 (+3.17%)
Prev Close
$0.91
Open
$0.90
Day's High
$0.94
Day's Low
$0.90
Volume
6,973
Avg. Vol
189,267
52-wk High
$17.76
52-wk Low
$0.89

Latest Key Developments (Source: Significant Developments)

Edge Therapeutics Reports Quarterly Loss Per Share $0.67
Tuesday, 1 May 2018 06:30am EDT 

May 1 (Reuters) - Edge Therapeutics Inc ::EDGE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.QUARTERLY LOSS PER SHARE $0.67.QTRLY LOSS PER SHARE BASIC AND DILUTED $0.67.SAYS BOARD CONDUCTING A COMPREHENSIVE REVIEW OF STRATEGIC ALTERNATIVES FOCUSED ON MAXIMIZING STOCKHOLDER VALUE.SAYS INTENDS TO STREAMLINE ITS OPERATIONS IN ORDER TO PRESERVE ITS CASH RESOURCES.SAYS HAS RETAINED PIPER JAFFRAY & CO. TO ACT AS ITS FINANCIAL ADVISOR TO ASSIST WITH THIS REVIEW PROCESS.  Full Article

Edge Therapeutics Reports Qtrly Loss Per Share $0.45
Thursday, 1 Mar 2018 06:30am EST 

March 1 (Reuters) - Edge Therapeutics Inc ::EDGE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.EDGE THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.45.EDGE THERAPEUTICS INC - SEES TOP-LINE RESULTS FROM FULL NEWTON 2 STUDY IN LATE 2018.  Full Article

Edge Therapeutics Says EG-1962 Phase 3 Study Continues As Planned Following Completion Of Futility Analysis
Friday, 29 Dec 2017 04:05pm EST 

Dec 29 (Reuters) - Edge Therapeutics Inc ::EDGE'S EG-1962 PHASE 3 NEWTON 2 STUDY CONTINUES AS PLANNED FOLLOWING COMPLETION OF FUTILITY ANALYSIS.EDGE THERAPEUTICS - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDED PHASE 3 NEWTON 2 STUDY OF EG-1962 CONTINUE AS PLANNED.  Full Article

Edge Therapeutics reports qtrly loss per share $‍0.37​
Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - Edge Therapeutics Inc :Edge Therapeutics reports third quarter 2017 financial results.Edge Therapeutics Inc - qtrly loss per share $‍0.37​.  Full Article

Edge Therapeutics qtrly loss per share $0.44
Tuesday, 1 Aug 2017 06:30am EDT 

Aug 1 (Reuters) - Edge Therapeutics Inc ::Edge Therapeutics reports second quarter 2017 financial results and continued operational progress.Edge Therapeutics Inc qtrly loss per share basic and diluted $0.44.Q2 earnings per share view $-0.44 -- Thomson Reuters I/B/E/S.  Full Article

Edge Therapeutics enters commercial supply agreement for EG-1962 with Oakwood Laboratories
Thursday, 6 Jul 2017 06:30am EDT 

July 6 (Reuters) - Edge Therapeutics Inc :Edge Therapeutics announces commercial supply agreement for EG-1962 with Oakwood Laboratories.Edge Therapeutics Inc - also entered agreement for initial product launch of EG-1962.Edge Therapeutics Inc - entered supply agreement, amended and restated development agreement with Oakwood Laboratories for manufacturing of EG-1962.  Full Article

Edge Therapeutics Qtrly loss per share $0.42
Wednesday, 3 May 2017 06:30am EDT 

May 3 (Reuters) - Edge Therapeutics Inc ::Edge Therapeutics reports first quarter 2017 financial results and continued operational progress.Qtrly loss per share $0.42.  Full Article

MUNEER SATTER REPORTS 5.8 PCT PASSIVE STAKE IN EDGE THERAPEUTICS AS OF APRIL 19
Tuesday, 25 Apr 2017 10:47am EDT 

April 25 (Reuters) - :MUNEER A SATTER REPORTS 5.8 PERCENT PASSIVE STAKE IN EDGE THERAPEUTICS INC AS OF APRIL 19, 2017 - SEC FILING.  Full Article

Edge Therapeutics files for offering up to 1.8 mln shares
Wednesday, 19 Apr 2017 06:56am EDT 

April 19 (Reuters) - Edge Therapeutics Inc :Edge Therapeutics Inc - files for offering of up to 1.8 million shares of co's common stock in registered direct offering at negotiated price of $10/share.  Full Article

Edge Therapeutics announces $18 mln registered direct offering of common stock
Wednesday, 19 Apr 2017 06:30am EDT 

April 19 (Reuters) - Edge Therapeutics Inc :Edge Therapeutics announces $18 million registered direct offering of common stock.Edge Therapeutics Inc- Entered into subscription agreement for sale of shares of its common stock.Says proceeds from offering will be used to advance pre-commercial activities for EG-1962.Edge Therapeutics Inc- Proceeds from offering will be used to advance pre-commercial activities for EG-1962.Edge Therapeutics Inc - Edge has agreed to sell to investors 1.8 million shares at a purchase price of $10.00 per share with gross proceeds of $18 million.  Full Article